Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Amortization of Deferred Charges: 2009-2016

Historic Amortization of Deferred Charges for UNITED THERAPEUTICS (UTHR) over the last 6 years, with Mar 2016 value amounting to $100,000.

  • UNITED THERAPEUTICS's Amortization of Deferred Charges fell 95.00% to $100,000 in Q1 2016 from the same period last year, while for Mar 2016 it was $4.0 million, marking a year-over-year decrease of 63.89%. This contributed to the annual value of $5.9 million for FY2015, which is 52.30% down from last year.
  • As of Q1 2016, UNITED THERAPEUTICS's Amortization of Deferred Charges stood at $100,000, which was down 76.91% from $433,000 recorded in Q4 2015.
  • Over the past 5 years, UNITED THERAPEUTICS's Amortization of Deferred Charges peaked at $3.4 million during Q3 2014, and registered a low of $100,000 during Q1 2016.
  • Over the past 3 years, UNITED THERAPEUTICS's median Amortization of Deferred Charges value was $2.5 million (recorded in 2014), while the average stood at $2.1 million.
  • In the last 5 years, UNITED THERAPEUTICS's Amortization of Deferred Charges spiked by 47.50% in 2013 and then plummeted by 95.00% in 2016.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Amortization of Deferred Charges stood at $2.2 million in 2012, then spiked by 47.50% to $3.2 million in 2013, then declined by 21.98% to $2.5 million in 2014, then slumped by 82.60% to $433,000 in 2015, then plummeted by 95.00% to $100,000 in 2016.
  • Its Amortization of Deferred Charges stands at $100,000 for Q1 2016, versus $433,000 for Q4 2015 and $408,000 for Q3 2015.